Abstract
Insulin Resistance (IR) is a cardinal feature of Type 2 Diabetes Mellitus (T2DM). It also is associated with multiple metabolic abnormalities which are known Cardiovascular Disease (CVD) risk factors. Thus, IR not only contributes to the development of hyperglycemia in T2DM patients, but also to the elevated CVD risk. Improving insulin sensitivity is anticipated to both lower the plasma glucose concentration and decrease CVD risk in T2DM patients, independent of glucose control. We review the molecular mechanisms and metabolic consequences of IR in T2DM patients and discuss the importance of addressing IR in the management of T2DM.
Original language | English (US) |
---|---|
Pages (from-to) | 153-163 |
Number of pages | 11 |
Journal | Current Vascular Pharmacology |
Volume | 17 |
Issue number | 2 |
DOIs | |
State | Published - 2018 |
Keywords
- Cardiovascular disease
- HDL
- Insulin resistance
- Insulin sensitizers
- LDL
- Type 2 diabetes
ASJC Scopus subject areas
- Pharmacology
- Cardiology and Cardiovascular Medicine